Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors

Additional Information

Published Date May 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5217
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors.

    To find out more about Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

This Report Includes the Following Companies:
4SC
A&G Pharmaceutical
AB Science
Abbott
Abiogen
Acceleron Pharma
ACT Biotech
Active Biotech
Adherex
Advanomics
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affimed Therapeutics
Agennix
Agenus
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allist Pharmaceuticals
Allos Therapeutics
Allostera
AlphaVax
Altor BioScience
Ambit Biosciences
Amgen
Amphora
AngioChem
Ansaris
Antisense Pharma
Antisoma
Anza Therapeutics
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Avila Therapeutics
Axelar
Bavarian Nordic
Bayer
Benitec
Berkeley Lab
Betapharma
Bio-Path Holdings
BioAxone
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biokine Therapeutics
Biolex
BioLineRx
Bionovo
BioNumerik
BioSante
Biotecnol
Biotica Technology
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Callisto Pharmaceuticals
Cambrex
CanBas
Cancer Research Technology
Catalyst Biosciences
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Celltrion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CerRx
CG Therapeutics
Chemokine Therapeutics
Chong Kun Dang
Chroma Therapeutics
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Clinical Data
CLL Pharma
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cornerstone Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokine PharmaSciences
Cytokinetics
Cytopia
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dong-A
Dr Reddy’s
Dyax
Dynavax Technologies
ECI
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Endocyte
Enkam Pharmaceuticals
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Exelixis
Favrille
Forma Therapeutics
Fresenius
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenPat77
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GlycoGenesys
GPC Biotech
Gradalis
Hanmi
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hy BioPharma
Hypha Discovery
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
ImmuPharma
Incozen Therapeutics
Incyte Corporation
Inex
Infinity Pharmaceuticals
Inhibiton Therapeutics
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intellikine
Intezyne Technologies
Intracel
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Jennerex Biotherapeutics
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
KaloBios
Kalypsys
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
Kissei
KuDOS
Kyowa Hakko Kirin
Leo
Lexicon Pharmaceuticals
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
Marina Biotech
MaxoCore Pharmaceuticals
Meda
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
Mitsubishi Tanabe Pharma
Molecular LogiX
MolMed
Mologen
Mycenax
Myrexis
Nano Terra
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
Noxxon
Nycomed Pharma
Oasmia
Oncalis
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
OXiGENE
Paladin Labs
PanaGin
Pathway Therapeutics
PBL Therapeutics
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Plexxikon
Portola Pharmaceuticals
Pro-Pharmaceuticals
Proacta
Progen Pharmaceuticals
Progenics Pharmaceuticals
ProNAi Therapeutics
Provid
QLT
Quantum Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Samtheo Biopharma
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
SGX Pharmaceuticals
ShimodaAtlantic Oncology
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
SRI International
Sunesis
SuperGen
SuppreMol
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
TauTaTis
Taxolog
TCD Pharma
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TransTech Pharma
TriAct Therapeutics
Trion Pharma
UCB
Vaccinex
Valeant
VasGene Therapeutics
Vaxon Biotech
VaxOnco
Velacor Therapeutics
VentiRx Pharmaceuticals
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
ViroMed
Wyeth
XBiotech
Xcovery
Xencor
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zenotech
Zenyaku Kogyo
Zhejiang Beta Pharma
Zivena
A Shortlist of Drugs Included are:
131I-tositumomab
AC-480
AE-37
AF-802
afatinib
aflibercept
alemtuzumab
alvocidib
AMG-386
amrubicin hydrochloride
Angiozyme
apatinib
AR-42
ARQ-197
astuprotimut-r
AT-7519
AT-9283
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
belagenpumatucel-L
belinostat
belotecan hydrochloride
bevacizumab
bexarotene
BEZ-235
BGT-226
BI-811283
BIBF-1120
BMS-690514
BMS-754807
BMS-777607
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
Cabozantinib
CAL-101
canfosfamide hydrochloride
CBP-501
CC-223
cediranib
celecoxib
cetuximab
cladribine
crizotinib
dacomitinib
danusertib
dasatinib
denileukin diftitox
dinaciclib
docetaxel
dovitinib lactate
E-75
elliptinium acetate
emepepimut-S
endostatin
endoxifen
ENMD-2076
enzastaurin hydrochloride
epirubicin
erlotinib
etoposide (1)
etoposide phosphate
everolimus
foretinib
fostamatinib disodium
galiximab
gefitinib
GSK-2118436
HBP-347
ibritumomab tiuxetan
IC-83
icotinib hydrochloride
icrucumab
idronoxil
imatinib mesilate
INCB-028060
iniparib
inotuzumab ozogamicin
INSM-18
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon (gamma1b)
interferon alfa-2b
interferon alpha-2b
irinotecan hydrochloride
JI-101
KD032
KX2-391
lapatinib ditosylate
lenvatinib
lestaurtinib
linifanib
linsitinib
LY-2090314
masitinib
MGCD-265
midostaurin
mitoxantrone
MK-1775
MKC-1
MLN-8237
MM-111
motesanib diphosphate
MVA-BN Her-2 vaccine
nadroparin
necitumumab
neratinib
nilotinib
nimotuzumab
NPB-001-056
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
onartuzumab
OSI-027
OTS-102
P276-00
paclitaxel
paclitaxel polyglumex
panobinostat
pazopanib hydrochloride
PD-0332991
pegdinetanib
pemetrexed disodium
perifosine
PHA-848125AC
pixantrone
plitidepsin
ponatinib
pralatrexate
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
ramucirumab
razoxane
Reditux
regorafenib
rhIFN-alpha
ridaforolimus
rilotumumab
rituximab
romidepsin
ruxolitinib
RX-0201-N
SCH-900776
seliciclib
sirolimus
sobuzoxane
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
talactoferrin alfa
talmapimod
tandutinib
tegafur + uracil
telatinib
temsirolimus
teniposide
terameprocol
thymalfasin
tivozanib
topotecan
triciribine phosphate
TS-1
vandetanib
varlitinib
vemurafenib
volasertib
vosaroxin
XL-147
XL-281
XL-413
XL-647
XL-765
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors.
    To find out more about Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Melanoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Triple Analysis: Breast Cancer, Leukemia and Antibodies
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Melanoma, Angiogenesis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Learn More


Triple Analysis: Leukemia, Angiogenesis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Learn More